NASDAQ:SGRY

Surgery Partners Stock Forecast, Price & News

$46.50
-0.05 (-0.11 %)
(As of 09/17/2021 12:00 AM ET)
Add
Compare
Today's Range
$45.81
$48.30
50-Day Range
$43.06
$63.10
52-Week Range
$18.25
$69.58
Volume419,892 shs
Average Volume405,029 shs
Market Capitalization$3.84 billion
P/E RatioN/A
Dividend YieldN/A
Beta3.15
30 days | 90 days | 365 days | Advanced Chart
Receive SGRY News and Ratings via Email

Sign-up to receive the latest news and ratings for Surgery Partners and its competitors with MarketBeat's FREE daily newsletter.


Surgery Partners logo

About Surgery Partners

Surgery Partners, Inc. is healthcare services holding company, which engages in the provision of solutions for surgical and related ancillary care in support of its patients and physicians. It operates through the following business segments: Surgical Facility Services, Ancillary Services, and Optical Services. The Surgical Facility Services segment consists of the operation of ambulatory surgery centers and surgical hospitals, including anesthesia services of the company. The Ancillary Services segment operates a diagnostic laboratory and multi-specialty physician practices. The Optical Services segment involves an optical laboratory and an optical products group purchasing organization. The company was founded in 2004 and is headquartered in Brentwood, TN.

Headlines

See More Headlines

Industry, Sector and Symbol

Sales & Book Value

Profitability

Debt

Price-To-Earnings

Miscellaneous


MarketRank

Overall MarketRank

1.87 out of 5 stars

Medical Sector

691st out of 1,349 stocks

General Medical & Surgical Hospitals Industry

5th out of 7 stocks

Analyst Opinion: 1.3Community Rank: 4.1Dividend Strength: 0.0Insider Behavior: 3.3Valuation: 0.6 5 -4 -3 -2 -1 -
speech bubbles
speech bubbles











Surgery Partners (NASDAQ:SGRY) Frequently Asked Questions

Is Surgery Partners a buy right now?

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Surgery Partners in the last twelve months. There are currently 2 hold ratings and 2 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" Surgery Partners stock.
View analyst ratings for Surgery Partners
or view top-rated stocks.

What stocks does MarketBeat like better than Surgery Partners?

Wall Street analysts have given Surgery Partners a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Surgery Partners wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

Are investors shorting Surgery Partners?

Surgery Partners saw a decline in short interest during the month of August. As of August 13th, there was short interest totaling 1,270,000 shares, a decline of 14.2% from the July 29th total of 1,480,000 shares. Based on an average daily trading volume, of 379,200 shares, the days-to-cover ratio is currently 3.3 days. Currently, 4.0% of the shares of the stock are sold short.
View Surgery Partners' Short Interest
.

When is Surgery Partners' next earnings date?

Surgery Partners is scheduled to release its next quarterly earnings announcement on Wednesday, November 3rd 2021.
View our earnings forecast for Surgery Partners
.

How were Surgery Partners' earnings last quarter?

Surgery Partners, Inc. (NASDAQ:SGRY) announced its quarterly earnings results on Wednesday, August, 4th. The company reported ($0.52) EPS for the quarter, missing analysts' consensus estimates of ($0.20) by $0.32. The firm had revenue of $543.30 million for the quarter, compared to analyst estimates of $545.08 million. Surgery Partners had a negative trailing twelve-month return on equity of 1.93% and a negative net margin of 4.95%.
View Surgery Partners' earnings history
.

How has Surgery Partners' stock been impacted by COVID-19 (Coronavirus)?

Surgery Partners' stock was trading at $8.86 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization. Since then, SGRY shares have increased by 424.8% and is now trading at $46.50.
View which stocks have been most impacted by COVID-19
.

What guidance has Surgery Partners issued on next quarter's earnings?

Surgery Partners issued an update on its FY 2021 earnings guidance on Wednesday, August, 25th. The company provided EPS guidance of for the period. The company issued revenue guidance of $2.20 billion-$2.23 billion, compared to the consensus revenue estimate of $2.23 billion.

What price target have analysts set for SGRY?

4 brokerages have issued twelve-month price targets for Surgery Partners' shares. Their forecasts range from $35.00 to $61.00. On average, they anticipate Surgery Partners' stock price to reach $48.67 in the next twelve months. This suggests a possible upside of 4.7% from the stock's current price.
View analysts' price targets for Surgery Partners
or view top-rated stocks among Wall Street analysts.

Who are Surgery Partners' key executives?

Surgery Partners' management team includes the following people:
  • J. Eric Evans, Chief Executive Officer & Director
  • Thomas F. Cowhey, CFO, Principal Accounting Officer & Executive VP
  • Varun Gadhok, Chief Information Officer & Senior Vice President
  • Roxanne Womack, Chief Compliance Officer & Senior Vice President
  • Jennifer B. Baldock, Secretary, Chief Administrative Officer & EVP (LinkedIn Profile)

What is Eric Evans' approval rating as Surgery Partners' CEO?

7 employees have rated Surgery Partners CEO Eric Evans on Glassdoor.com. Eric Evans has an approval rating of 86% among Surgery Partners' employees.

Who are some of Surgery Partners' key competitors?

What other stocks do shareholders of Surgery Partners own?

What is Surgery Partners' stock symbol?

Surgery Partners trades on the NASDAQ under the ticker symbol "SGRY."

Who are Surgery Partners' major shareholders?

Surgery Partners' stock is owned by a variety of retail and institutional investors. Top institutional shareholders include Bain Capital Investors LLC (59.49%), FMR LLC (12.13%), Clearbridge Investments LLC (5.91%), Vanguard Group Inc. (5.18%), Price T Rowe Associates Inc. MD (3.26%) and BlackRock Inc. (3.46%). Company insiders that own Surgery Partners stock include Anthony Taparo, George Goodwin, Jennifer Baldock, Laura L Brocklehurst, Teresa Deluca and Thomas F Cowhey.
View institutional ownership trends for Surgery Partners
.

Which institutional investors are selling Surgery Partners stock?

SGRY stock was sold by a variety of institutional investors in the last quarter, including Parallax Volatility Advisers L.P., Castleark Management LLC, Goldman Sachs Group Inc., Clearbridge Investments LLC, WCM Investment Management LLC, BNP Paribas Arbitrage SA, Price T Rowe Associates Inc. MD, and Calamos Advisors LLC. Company insiders that have sold Surgery Partners company stock in the last year include Anthony Taparo, George Goodwin, Jennifer Baldock, Laura L Brocklehurst, Teresa Deluca, and Thomas F Cowhey.
View insider buying and selling activity for Surgery Partners
or view top insider-selling stocks.

Which institutional investors are buying Surgery Partners stock?

SGRY stock was bought by a variety of institutional investors in the last quarter, including Bain Capital Investors LLC, Vanguard Group Inc., FMR LLC, Rheos Capital Works Inc., Hood River Capital Management LLC, Dimensional Fund Advisors LP, First Trust Advisors LP, and BlackRock Inc..
View insider buying and selling activity for Surgery Partners
or or view top insider-buying stocks.

How do I buy shares of Surgery Partners?

Shares of SGRY can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Surgery Partners' stock price today?

One share of SGRY stock can currently be purchased for approximately $46.50.

How much money does Surgery Partners make?

Surgery Partners has a market capitalization of $3.84 billion and generates $1.86 billion in revenue each year. The company earns $-116,100,000.00 in net income (profit) each year or ($1.49) on an earnings per share basis.

How many employees does Surgery Partners have?

Surgery Partners employs 10,800 workers across the globe.

What is Surgery Partners' official website?

The official website for Surgery Partners is www.surgerypartners.com.

Where are Surgery Partners' headquarters?

Surgery Partners is headquartered at 310 Seven Springs Way Suite 500, Brentwood TN, 37027.

How can I contact Surgery Partners?

Surgery Partners' mailing address is 310 Seven Springs Way Suite 500, Brentwood TN, 37027. The company can be reached via phone at (615) 234-5900 or via email at [email protected].


This page was last updated on 9/19/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.